🔗 Share this article

A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Experimental Drug Acquiring Traction Online

Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing effects. Viewers are encouraged to contact these accounts privately for source information, while also receiving promotional offers.

Active Trade on Social Networks

Separately, a flourishing trade exists on Telegram, where groups with thousands of participants share “before and after” photos, administration instructions and claims of next-day British shipping. Sellers market the substance there before directing customers to WhatsApp for transactions.

Learning About Retatrutide

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Voice Concerns

However, doctors and pharmacists have warned that the distribution of what is still an unapproved medication in the UK is worrisome and could result in users administering substances of unknown origin.

Some experts said the popularity for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unlicensed medication that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Some influencers try to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, advertising, and customer laws, risking fines, legal action or imprisonment.

Service Response and Material Removal

Based on the social media company, the platform has taken down violative content and banned associated hashtags and query recommendations. The company said it was committed to keeping the service safe and investing in strengthening enforcement strategies.

Digital Trading Activities

Investigations also discovered groups with up to 9,000 members selling the experimental drug using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” immediately displays groups with numerous of members, filled with photos of slimming results, glowing reviews and detailed instructions for preparing or administering at home.

Within moments of entering one community, a vendor posted WhatsApp details, where most transactions occur. The seller provided an guidebook and promised shipping within 48 hours. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one inquired about body mass, medical conditions or past usage.

Item Details and Pricing

Inside these groups, posts display black plastic packages with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at home with purified liquid, or pre-filled injectors usually priced at 160 pounds for 20 milligrams. When questioned how long a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Measures

A representative for the messaging service said it regularly moderated harmful material on its service including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are administering substances they can’t verify. Although the science behind this drug is sound, these digital versions may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using social media. But counterfeit injections are highly risky. You cannot know what’s contained or whether the conditions they were produced in was clean,” she said.

Her team has previously seen individuals harmed by personal administration from unconfirmed sources. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly said the substance was in phase 3 clinical trials and had not been reviewed or approved by any government authority globally. “Consequently at this time no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may subject patients to potentially significant medical dangers”.